| Mechanical Circulatory Support Devices | Lifetime | 660 | JP 12 | 97.46 |
| Cardiac Structural Anomalies and Repair | Lifetime | 850 | JP 18 | 97.75 |
| Electrolyte and hormonal disorders | Lifetime | 667 | JP 30 | 95.02 |
| Potassium and Related Disorders | Lifetime | 580 | JP 16 | 90.15 |
| Heart rate and cardiovascular health | Lifetime | 202 | JP 13 | 87.95 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 125 | JP 4 | 95.46 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 300 | JP 7 | 96.54 |
| Heart rate and cardiovascular health | 2021-2025 | 6 | JP 1 | 93.65 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 381 | JP 5 | 95.65 |
| Mechanical Circulatory Support Devices | 2021-2025 | 381 | JP 10 | 95.32 |
| Cardiac Arrhythmias and Treatments | 2021-2025 | 542 | JP 29 | 95.71 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 741 | JP 35 | 95.27 |
| Heart Failure Treatment and Management | 2021-2025 | 442 | JP 27 | 94.68 |
| Cardiac Valve Diseases and Treatments | 2021-2025 | 803 | JP 23 | 95.12 |
| Atrial Fibrillation Management and Outcomes | 2021-2025 | 919 | JP 66 | 93.98 |
| Electrolyte and hormonal disorders | 2021-2025 | 105 | JP 4 | 90.08 |
| Potassium and Related Disorders | 2021-2025 | 86 | JP 4 | 92.57 |
| Diabetes Treatment and Management | 2021-2025 | 811 | JP 31 | 91.91 |
| Cardiac electrophysiology and arrhythmias | 2021-2025 | 700 | JP 40 | 91.79 |
| Pulmonary Hypertension Research and Treatments | 2021-2025 | 609 | JP 43 | 89.20 |
| Cardiac tumors and thrombi | 2021-2025 | 460 | JP 43 | 78.01 |
| Amyloidosis: Diagnosis, Treatment, Outcomes | 2021-2025 | 642 | JP 41 | 81.44 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 228 | JP 23 | 80.69 |
| Hormonal Regulation and Hypertension | 2021-2025 | 809 | JP 66 | 81.32 |
| Non-Invasive Vital Sign Monitoring | 2021-2025 | 989 | JP 22 | 80.00 |
| Ultrasound in Clinical Applications | 2021-2025 | 756 | JP 17 | 77.10 |
| Ion Transport and Channel Regulation | 2021-2025 | 246 | JP 13 | 74.59 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 929 | JP 26 | 68.41 |
| Cardiovascular and Diving-Related Complications | 2021-2025 | 640 | JP 24 | 64.82 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 332 | JP 15 | 62.16 |
| Pericarditis and Cardiac Tamponade | 2021-2025 | 465 | JP 15 | 61.82 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 978 | JP 66 | 57.52 |
| Magnesium in Health and Disease | 2021-2025 | 425 | JP 38 | 52.63 |